Evidence lacking for long-term opioid use in low back pain

Evidence lacking for long-term opioid use in low back pain

(HealthDay)—There is evidence of short-term efficacy (moderate for pain and small for function) of opioids for treatment of chronic low back pain (CLBP) compared with placebo; however, the effectiveness and safety of long-term opioid therapy for treatment of CLBP remains unproven, according to a review published in the April 1 issue of Spine.

Luis Enrique Chaparro, M.D., from Hospital Pablo Tobon Uribe in Medellin, Columbia, and colleagues updated a 2007 Cochrane Review to assess the efficacy of opioids in adults with CLBP. Randomized controlled trials (through October 2012) assessing the use of noninjectable opioids in CLBP for at least four weeks versus or other treatments were included. However, comparisons of different opioids were excluded.

The researchers found that 15 trials (5,540 participants), including twelve new trials, met the criteria. Compared to placebo, tramadol was better for pain and function, while transdermal buprenorphine decreased pain, compared to placebo, but did not affect function. Broadly, strong opioids (including morphine, hydromorphone, oxycodone, oxymorphone, and tapentadol) were better for pain and function than placebo. There was no difference between opioids and antidepressants for pain or function in two trials (272 participants). There were no reports of serious adverse effects, risks (addiction or overdose), or complications (sleep apnea, opioid-induced hyperalgesia, hypogonadism). Quality of the trials was low to moderate and the trials also had high dropout rates, short duration, and limited interpretability of functional improvement.

"There is evidence of short-term efficacy (moderate for and small for function) of to treat CLBP compared with placebo," the authors write.

Relevant financial activities outside the submitted work were reported: board membership, consultancy, honoraria, employment, and royalties

More information: Full Text

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

3 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.